|
1
|
Sant M, Capocaccia R, Coleman MP, et al:
Cancer survival increases in Europe, but international differences
remain wide. Eur J Cancer. 37:1659–1667. 2001. View Article : Google Scholar
|
|
2
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I: Recent cancer survival
in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet
Oncol. 8:784–796. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aarntzen EH, Figdor CG, Adema GJ, Punt CJ
and de Vries IJ: Dendritic cell vaccination and immune monitoring.
Cancer Immunol Immunother. 57:1559–1568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosenberg SA, Restifo NP, Yang JC, Morgan
RA and Dudley ME: Adoptive cell transfer: a clinical path to
effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perez SA, von Hofe E, Kallinteris NL,
Gritzapis AD, Peoples GE, Papamichail M and Baxevanis CN: A new era
in anticancer peptide vaccines. Cancer. 116:2071–2080.
2010.PubMed/NCBI
|
|
6
|
Nakatsura T, Yoshitake Y, Senju S, et al:
Glypican-3, overexpressed specifically in human hepatocellular
carcinoma, is a novel tumor marker. Biochem Biophys Res Commun.
306:16–25. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shirakawa H, Suzuki H, Shimomura M, et al:
Glypican-3 expression is correlated with poor prognosis in
hepatocellular carcinoma. Cancer Sci. 100:1403–1407. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nakatsura T, Komori H, Kubo T, et al:
Mouse homologue of a novel human oncofetal antigen, glypican-3,
evokes T-cell-mediated tumor rejection without autoimmune reactions
in mice. Clin Cancer Res. 10:8630–8640. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Komori H, Nakatsura T, Senju S, et al:
Identification of HLA-A2- or HLA-A24-restricted CTL epitopes
possibly useful for glypican-3-specific immunotherapy of
hepatocellular carcinoma. Clin Cancer Res. 12:2689–2697. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Motomura Y, Ikuta Y, Kuronuma T, et al:
HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine
induces specific CTLs: preclinical study using mice. Int J Oncol.
32:985–990. 2008.PubMed/NCBI
|
|
11
|
Sawada Y, Yoshikawa T, Nobuoka D, et al:
Phase I trial of a glypican-3-derived peptide vaccine for advanced
hepatocellular carcinoma: immunologic evidence and potential for
improving overall survival. Clin Cancer Res. 18:3686–3696. 2012.
View Article : Google Scholar
|
|
12
|
Sawada Y, Sakai M, Yoshikawa T, Ofuji K
and Nakatsura T: A glypican-3-derived peptide vaccine against
hepatocellular carcinoma. Oncoimmunology. 1:1448–1450. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rosenberg SA: Cell transfer immunotherapy
for metastatic solid cancer - what clinicians need to know. Nat Rev
Clin Oncol. 8:577–585. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gomes AQ, Martins DS and Silva-Santos B:
Targeting gamma-delta T lymphocytes for cancer immunotherapy: from
novel mechanistic insight to clinical application. Cancer Res.
70:10024–10027. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilhelm M, Kunzmann V, Eckstein S, Reimer
P, Weissinger F, Ruediger T and Tony HP: Gammadelta T cells for
immune therapy of patients with lymphoid malignancies. Blood.
102:200–206. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakamoto M, Nakajima J, Murakawa T, et al:
Adoptive immunotherapy for advanced non-small cell lung cancer
using zoledronate-expanded gammadelta T cells: a phase I clinical
study. J Immunother. 34:202–211. 2011. View Article : Google Scholar
|
|
17
|
Nakajima J, Murakawa T, Fukami T, et al: A
phase I study of adoptive immunotherapy for recurrent
non-small-cell lung cancer patients with autologous gammadelta T
cells. Eur J Cardiothorac Surg. 37:1191–1197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Champagne E: Gammadelta T cell receptor
ligands and modes of antigen recognition. Arch Immunol Ther Exp
(Warsz). 59:117–137. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nedellec S, Bonneville M and Scotet E:
Human Vgamma9Vdelta2 T cells: from signals to functions. Semin
Immunol. 22:199–206. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mookerjee-Basu J, Vantourout P, Martinez
LO, et al: F1-adenosine triphosphatase displays properties
characteristic of an antigen presentation molecule for
Vgamma9Vdelta2 T cells. J Immunol. 184:6920–6928. 2010. View Article : Google Scholar
|
|
21
|
Gober HJ, Kistowska M, Angman L, Jeno P,
Mori L and De Libero G: Human T cell receptor gammadelta cells
recognize endogenous mevalonate metabolites in tumor cells. J Exp
Med. 197:163–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gomes AQ, Correia DV, Grosso AR, et al:
Identification of a panel of ten cell surface protein antigens
associated with immunotargeting of leukemias and lymphomas by
peripheral blood gammadelta T cells. Haematologica. 95:1397–1404.
2010. View Article : Google Scholar
|
|
23
|
D’Asaro M, La Mendola C, Di Liberto D, et
al: V gamma 9V delta 2 T lymphocytes efficiently recognize and kill
zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant
chronic myelogenous leukemia cells. J Immunol. 184:3260–3268.
2010.
|
|
24
|
Chargui J, Combaret V, Scaglione V, et al:
Bromohydrin pyrophosphate-stimulated Vgamma9delta2 T cells expanded
ex vivo from patients with poor-prognosis neuroblastoma lyse
autologous primary tumor cells. J Immunother. 33:591–598. 2010.
View Article : Google Scholar
|
|
25
|
Todaro M, D’Asaro M, Caccamo N, et al:
Efficient killing of human colon cancer stem cells by gammadelta T
lymphocytes. J Immunol. 182:7287–7296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gertner-Dardenne J, Bonnafous C, Bezombes
C, et al: Bromohydrin pyrophosphate enhances antibody-dependent
cell-mediated cytotoxicity induced by therapeutic antibodies.
Blood. 113:4875–4884. 2009. View Article : Google Scholar
|
|
27
|
Capietto AH, Martinet L and Fournie J:
Stimulated gamma-delta T cells increase the in vivo efficacy of
trastuzumab in HER-2+ breast cancer. J Immunol.
187:1031–1038. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Takahara M, Miyai M, Tomiyama M, Mutou M,
Nicol AJ and Nieda M: Copulsing tumor antigen-pulsed dendritic
cells with zoledronate efficiently enhance the expansion of tumor
antigen-specific CD8+ T cells via Vgamma9gammadelta T
cell activation. J Leukoc Biol. 83:742–754. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Correia DV, d’Orey F, Cardoso BA, et al:
Highly active microbial phosphoantigen induces rapid yet sustained
MEK/Erk- and PI-3K/Akt-mediated signal transduction in anti-tumor
human gammadelta T-cells. PLoS One. 4:e56572009. View Article : Google Scholar
|
|
30
|
Brandes M, Willimann K and Moser B:
Professional antigen-presentation function by human gammadelta T
cells. Science. 309:264–268. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Moser B and Eberl M: Gammadelta T-APCs: a
novel tool for immunotherapy? Cell Mol Life Sci. 68:2443–2452.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Landmeier S, Altvater B, Pscherer S, et
al: Activated human gammadelta T cells as stimulators of specific
CD8+ T-cell responses to subdominant Epstein Barr virus
epitopes: potential for immunotherapy of cancer. J Immunother.
32:310–321. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Altvater B, Pscherer S, Landmeier S,
Kailayangiri S, Savoldo B, Juergens H and Rossig C: Activated human
gammadelta T cells induce peptide-specific CD8+ T-cell
responses to tumor-associated self-antigens. Cancer Immunol
Immunother. 61:385–396. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoshikawa T, Nakatsugawa M, Suzuki S, et
al: HLA-A2-restricted glypican-3 peptide-specific CTL clones
induced by peptide vaccine show high avidity and antigen-specific
killing activity against tumor cells. Cancer Sci. 102:918–925.
2011. View Article : Google Scholar
|
|
35
|
Robbins PF, Morgan RA, Feldman SA, et al:
Tumor regression in patients with metastatic synovial cell sarcoma
and melanoma using genetically engineered lymphocytes reactive with
NY-ESO-1. J Clin Oncol. 29:917–924. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sadelain M, Brentjens R and Riviere I: The
basic principles of chimeric antigen receptor design. Cancer
Discov. 3:388–398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Porter DL, Levine BL, Kalos M, Bagg A and
June CH: Chimeric antigen receptor-modified T cells in chronic
lymphoid leukemia. N Engl J Med. 365:725–733. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weber J, Atkins M, Hwu P, Radvanyi L,
Sznol M and Yee C: White paper on adoptive cell therapy for cancer
with tumor-infiltrating lymphocytes: a report of the CTEP
subcommittee on adoptive cell therapy. Clin Cancer Res.
17:1664–1673. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Nakatsura T, Kageshita T, Ito S, et al:
Identification of glypican-3 as a novel tumor marker for melanoma.
Clin Cancer Res. 10:6612–6621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Saikali Z and Sinnett D: Expression of
glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 89:418–422.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Toretsky JA, Zitomersky NL, Eskenazi AE,
et al: Glypican-3 expression in Wilms tumor and hepatoblastoma. J
Pediatr Hematol Oncol. 23:496–499. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Maeda D, Ota S, Takazawa Y, et al:
Glypican-3 expression in clear cell adenocarcinoma of the ovary.
Mod Pathol. 22:824–832. 2009.PubMed/NCBI
|
|
43
|
Aviel-Ronen S, Lau SK, Pintilie M, Lau D,
Liu N, Tsao MS and Jothy S: Glypican-3 is overexpressed in lung
squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol.
21:817–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nobuoka D, Yoshikawa T, Takahashi M, et
al: Intratumoral peptide injection enhances tumor cell antigenicity
recognized by cytotoxic T lymphocytes: a potential option for
improvement in antigen-specific cancer immunotherapy. Cancer
Immunol Immunother. 62:639–652. 2013. View Article : Google Scholar
|
|
45
|
Nobuoka D, Yoshikawa T, Fujiwara T and
Nakatsura T: Peptide intra-tumor injection for cancer
immunotherapy: enhancement of tumor cell antigenicity is a novel
and attractive strategy. Hum Vaccin Immunother. 9:1234–1236. 2013.
View Article : Google Scholar : PubMed/NCBI
|
